Chanticleer Holdings Announces Merger Agreement with Sonnet BioTherapeutics to Advance Pipeline of Novel Immune Therapeutics
(WorldNews Health)

Chanticleer Holdings Announces Merger Agreement with Sonnet BioTherapeutics to Advance Pipeline of Novel Immune Therapeutics October 10, 2019 - Transaction to Accelerate Sonnet`s Growing Pipeline of Oncology Candidates - - Initiation of Two New Clinical Programs Expected in 2020 - - Strategic Expansion of Sonnet`s Proprietary Platform - - Chanticleer to Spin-Off Existing Operations - CHARLOTTE, N.C. and PRINCETON, N.J., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Chanticleer Holdings, Inc. (Nasdaq: BURG) and Sonnet BioTherapeutics, Inc., a privately-held clinical stage biopharmaceutical company developing innovative targeted biologic drugs, announced today they have entered into a definitive merger...